<DOC>
	<DOC>NCT01671059</DOC>
	<brief_summary>This non-interventional study evaluated the use and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis. Eligible participants initiated on tocilizumab treatment according to the approved label were followed for 6 months.</brief_summary>
	<brief_title>A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab (RoActemra/Actemra)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult participants, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria Participants in whom the treating physician made the decision to commence tocilizumab treatment (in accordance with the local label); this could include participants who had received tocilizumab treatment within 8 weeks prior to the enrollment visit Participants who had received tocilizumab more than 8 weeks prior to the enrollment visit Participants who had previously received tocilizumab in a clinical trial or for compassionate use Treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever was longer) before starting treatment with tocilizumab History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>